<DOC>
	<DOCNO>NCT02784561</DOCNO>
	<brief_summary>The purpose study determine safety efficacy Busulfan/FLAG ( fludarabine , cytarabine granulocyte colony-stimulating factor ) Conditioning Regimen Patients Relapsed/refractory Acute Leukemia undergo allogeneic peripheral blood stem cell transplantation .</brief_summary>
	<brief_title>Study Busulfan FLAG Conditioning Regimen Allogeneic Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( allo-SCT ) way cure relapsed/refractory acute leukemia . Busulfan/Cyclophosphamide ( BuCy , Cytarabine , Busulfan , Cyclophosphamide ) classical condition regimen allo-SCT . Substitution Cyclophosphamide BuCy regimen Fludarabine ( BuF ) result reduce toxicity similar efficacy . FLAG ( fludarabine , cytarabine granulocyte colony-stimulating factor ) chemotherapy regimen prove effective relapsed/refractory acute leukemia salvage therapy . To reduce relapse improve survival patient relapsed/refractory acute leukemia receive allo-SCT , novel condition regimen consist Busulfan/FLAG develop . The combination Bu FLAG without interval shortens duration condition pneutropenic period patient compare successive administration FLAG follow BuF . In addition , regard establish safety efficacy BuF FLAG , reasonable expect similar safety enhance antileukemic efficacy Bu/FLAG compare BuF . In study , safety efficacy regimen patient relapsed/refractory acute leukemia undergo allogeneic peripheral blood stem cell transplantation investigate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>relapsed/refractory acute leukemia regardless cytogenetics All patient age 12 65 year Have match sibling donor , â‰¥8/10 HLA ( human leukocyte antigen ) match unrelated donor haploidentical donor Patients without uncontrolled infection without severe pulmonary , renal , hepatic cardiac diseases Patients age less 12 year old Patients uncontrolled infection severe pulmonary , renal , hepatic cardiac disease Acute myeloid leukemia patient ( 15 ; 17 )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>allogeneic peripheral blood stem cell transplantation</keyword>
	<keyword>condition regimen</keyword>
	<keyword>acute leukemia</keyword>
	<keyword>relapsed/refractory</keyword>
</DOC>